高尿酸血症・痛風の治療ガイドラインと尿酸トランスポーター関連薬剤の概要

Abstract

Uric acid (UA) transporters, including urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), and ATP-binding cassette subfamily G member 2 (ABCG2), are involved in hyperuricemia. A novel selective urate reabsorption inhibitor, developed in Japan, reduces serum UA levels by selectively inhibiting URAT1. The Japanese Society of Gout and Nucleic Acid Metabolism published "Guidelines for the Management of Hyperuricemia and Gout (3rd edition, 2022-Supplementary Edition-)" in March 2022. This guideline provides valuable information for decision-making in clinical management of hyperuricemia.